Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.8365
-0.0066 (-0.78%)
Oct 6, 2026, 9:24 AM EDT - Market open
Daré Bioscience Revenue
Daré Bioscience had revenue of $187.55K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.37M. In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.36% growth.
Revenue (ttm)
$1.37M
Revenue Growth
+10,429.36%
P/S Ratio
9.44
Revenue / Employee
$56,914
Employees
24
Market Cap
12.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.36% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Vistagen Therapeutics | 2.50M |
| BioLineRx | 1.39M |
| Pluri | 1.02M |
| Vyome Holdings | 129.73K |
| Lisata Therapeutics | 100.00K |
DARE News
- 8 days ago - Dare Bioscience announces issuance of patent for DARE-HPV program - TheFly
- 8 days ago - Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection - GlobeNewsWire
- 13 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 22 days ago - Dare Bioscience publishes results from Sildenafil Cream study - TheFly
- 22 days ago - Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil - GlobeNewsWire
- 25 days ago - Daré Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 25 days ago - Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand - GlobeNewsWire
- 27 days ago - Daré Bioscience Slides: Corporate presentation - Filings